Vical completes enrollment in Phase II of HSV-2 vaccine

In April, Vical Inc. (NASDAQ:VICL) completed enrollment of 225 adults with symptomatic genital herpes simplex virus type 2 (HSV-2) infection in a Phase II trial evaluating 1 mL intramuscular VCL-HB01 (HSV-2 vaccine, Vaxfectin-formulated plasmid DNA HSV-2 vaccine) every 28 days for 4 doses. The double-blind, placebo-controlled, U.S. trial's primary endpoint is lesion recurrences. Secondary endpoints include safety, time to first recurrence and proportion of patients who are recurrence free.

Vical expects to report top-line data in 2Q18...